"Advancements in oral insulin development: are we nearly there yet?"
Insights from Dr. Eric Zijlstra, Executive Project Director at Profil:
The live online seminar will take place on November 2nd, 2021 at 4 PM CEST.
You will benefit by learning about:
- Oral insulin as mealtime, support and basal insulin therapy
- Current status of oral insulin development
- The future for oral insulin therapy after emergence of ultrafast-acting insulins and closed-loop technologies
Online Seminar synopsis
In 1923, not more than two years after Frederick Banting & Charles Best had isolated insulin from pancreatic tissue in dogs, the first experiments with orally administered insulin were conducted. Fast forward, almost 100 years later, no insulin pill or tablet is commercially available. Despite the lack of success in developing an oral insulin, an oral insulin replacement therapy remains a very appealing alternative to subcutaneous injections for many patients with diabetes. All oral insulin formulations tested to date exhibit a need for high amounts of insulin to be administered in order to see a glucose lowering effects. This has lead to discontinuation of various developments.
To continue the search for an oral insulin pill, technological advances to increase insulin absorption from the gastrointestinal tract are needed. Nanotechnology and ingestible insulin application systems are amongst newly proposed ideas that may provide an oral insulin delivery platform in the future.
In this online seminar we will emphasize how to optimise and conduct a clinical trial for oral insulins.
Who should attend this online seminar
This online seminar is aimed at all interested in oral insulin development.
After the session you will be up-to-date on the current status of oral insulins.
Meet the presenter
Dr. Eric Zijlstra is a research scientist and expert in the field of diabetes technology, alternative route administrations of insulin and glucose clamp studies. Eric is part of the Profil leadership team and oversees clinical trial preparations and operations at the site in Neuss, Germany. He has worked on more than 100 clinical trials and has communicated his research findings at all major international diabetes conferences.
Share this online seminar with your colleagues: